- In patients with Hodgkin lymphoma (HL), baseline vitamin D deficiency was significantly associated with inferior long-term tumor control and OS.
Why this matters
- Vitamin D deficiency has been linked to the incidence of several cancers, but has not previously been evaluated with regard to HL.
- Study to investigate associations between pretreatment vitamin D levels and outcomes in 351 first-line patients from the German Hodgkin Study Group clinical trials (HD7, HD8, and HD9).
- Vitamin D deficiency was defined as 25-hydroxyvitamin D
- Funding: None disclosed.
- 50% of treatment-naive patients were vitamin D deficient at baseline.
- 68% of patients with relapsed/refractory disease had baseline vitamin D deficiency vs 41% of relapse-free control individuals (P<.001>
- Significantly inferior PFS with baseline vitamin D deficiency vs with sufficient or insufficient levels:
- 5-year difference: 10.2% (95% CI, 0.8%-19.6%).
- 10-year difference: 17.6% (95% CI, 6.9%-28.4%); HR, 2.13 (95% CI, 1.84-2.48; P<.001>
- Significantly inferior OS with baseline vitamin D deficiency vs with sufficient or insufficient levels:
- 5-year difference: 2.0% (95% CI, −5.3% to 9.3%).
- 10-year difference: 11.1% (95% CI, 2.1%-20.2%); HR, 1.82 (95% CI, 1.53-2.15; P<.001>
- Retrospective data.